Pylarify (F18 piflufolastat)
Ended Awarded Last action
- Contract number
- 36C25025N0042
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,064,938
Award facts
- Contract value 100% obligated
- $1,064,937.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$35,722 | |
| Original award | $1,100,660 |
About this award
Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging Inc., received a $1.06M delivery order from Veterans Integrated Service Network 10 on October 1, 2024, for PYLARIFY (F18 piflufolastat), a diagnostic radiopharmaceutical used in positron emission tomography scans to detect and image prostate cancer. This modification to the delivery order de-obligated excess funds and carries a firm fixed-price contract structure with a completion date of September 30, 2025. The contract was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and does not include a set-aside designation. The place of performance is North Billerica, Massachusetts.
This delivery order represents a continuation of the Department of Veterans Affairs' ongoing procurement of critical diagnostic imaging agents to support medical imaging programs across VA medical centers. Progenics Pharmaceuticals, through its parent company Lantheus Holdings Inc., maintains significant indefinite delivery vehicles with the VA and Defense Health Agency, including a $290M Federal Supply Schedule contract and multiple blanket purchase agreements. These contract vehicles enable efficient procurement of radiopharmaceuticals across federal healthcare providers, including military treatment facilities and VA medical centers nationwide.
Quick answers
Who was awarded contract 36C25025N0042?
36C25025N0042 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C25025N0042 worth?
The government has obligated $1,064,938 on 36C25025N0042.
Is contract 36C25025N0042 an order under another contract?
Yes. 36C25025N0042 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25025N0042 competed?
The extent of competition for 36C25025N0042 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award